Skip to main content
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. — Investor Relations & Filings

Ticker · APRE ISIN · US03836J1025 US Professional, scientific and technical activities
Filings indexed 405 across all filing types
Latest filing 2020-03-26 Director's Dealing
Country US United States of America
Listing US APRE

About Aprea Therapeutics, Inc.

https://www.aprea.com/

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel cancer therapeutics. The company focuses on precision oncology through a synthetic lethality-based approach, targeting DNA Damage Response (DDR) pathways. Its pipeline consists of small molecule therapeutics designed to exploit vulnerabilities associated with cancer cell mutations, aiming to maximize clinical activity and selectivity while minimizing toxicity. Aprea Therapeutics is conducting clinical trials to evaluate its programs in patients with advanced solid tumors.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2020-03-26 English
4
Director's Dealing
2020-03-26 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 26, 2020, by Aprea Therapeutics, Inc. It announces the issuance of a press release regarding financial results for the fourth quarter and year ended December 31, 2019. The document itself is short (3980 characters) and primarily serves to furnish the press release as an exhibit. It does not contain the full financial report or detailed financial statements but rather announces the results and provides the press release as an attachment. According to the 'Menu vs Meal' rule, such a document is an announcement of a report rather than the report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-03-26 English
JANUS HENDERSON GROUP PLC OWNS 8.6% OF APREA
Major Shareholding Notification
2020-02-14 English
SC 13G
Major Shareholding Notification
2020-02-14 English
SCHEDULE 13G
Major Shareholding Notification
2020-02-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.